Burns J W & Co. Inc. NY Sells 160 Shares of Novartis AG (NYSE:NVS)

Burns J W & Co. Inc. NY trimmed its position in shares of Novartis AG (NYSE:NVS) by 1.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 15,571 shares of the company’s stock after selling 160 shares during the quarter. Burns J W & Co. Inc. NY’s holdings in Novartis were worth $1,353,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Winslow Evans & Crocker Inc. raised its holdings in Novartis by 11.8% in the 2nd quarter. Winslow Evans & Crocker Inc. now owns 1,084 shares of the company’s stock worth $102,000 after acquiring an additional 114 shares during the last quarter. PagnatoKarp Partners LLC raised its holdings in Novartis by 0.6% in the 2nd quarter. PagnatoKarp Partners LLC now owns 18,887 shares of the company’s stock worth $1,725,000 after acquiring an additional 115 shares during the last quarter. Old Port Advisors raised its holdings in Novartis by 4.5% in the 2nd quarter. Old Port Advisors now owns 2,722 shares of the company’s stock worth $252,000 after acquiring an additional 116 shares during the last quarter. IHT Wealth Management LLC raised its holdings in Novartis by 3.6% in the 2nd quarter. IHT Wealth Management LLC now owns 3,514 shares of the company’s stock worth $321,000 after acquiring an additional 123 shares during the last quarter. Finally, Archford Capital Strategies LLC raised its holdings in Novartis by 5.7% in the 1st quarter. Archford Capital Strategies LLC now owns 2,447 shares of the company’s stock worth $235,000 after acquiring an additional 131 shares during the last quarter. Hedge funds and other institutional investors own 11.19% of the company’s stock.

NVS traded up $0.88 during mid-day trading on Friday, reaching $86.81. 27,724 shares of the company traded hands, compared to its average volume of 1,838,232. Novartis AG has a 52-week low of $71.86 and a 52-week high of $95.00. The company’s fifty day moving average price is $87.73 and its 200-day moving average price is $87.94. The company has a quick ratio of 0.74, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $195.54 billion, a P/E ratio of 17.05, a P/E/G ratio of 2.27 and a beta of 0.59.



Novartis (NYSE:NVS) last issued its quarterly earnings data on Thursday, July 18th. The company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.20 by $0.14. Novartis had a net margin of 23.27% and a return on equity of 18.55%. The firm had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $11.45 billion. During the same quarter in the previous year, the firm posted $1.29 EPS. The company’s revenue for the quarter was up 3.7% compared to the same quarter last year. As a group, sell-side analysts forecast that Novartis AG will post 5.15 earnings per share for the current fiscal year.

A number of brokerages recently weighed in on NVS. Jefferies Financial Group restated a “buy” rating on shares of Novartis in a report on Thursday, August 29th. Argus boosted their target price on shares of Novartis to $105.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. They noted that the move was a valuation call. ValuEngine lowered shares of Novartis from a “hold” rating to a “sell” rating in a research note on Thursday, September 12th. Zacks Investment Research lowered shares of Novartis from a “buy” rating to a “hold” rating and set a $100.00 target price for the company. in a research note on Friday, July 19th. Finally, Kepler Capital Markets lowered shares of Novartis from a “buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Five research analysts have rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Novartis has an average rating of “Hold” and an average target price of $93.29.

About Novartis

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.

Further Reading: What is a blue-chip stock?

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.